CEO David Happel Unloads $497K of Sagimet Stock at $7.76
SGMT sits 57% above its 52-week low of $4.5.
Summary
Sagimet Biosciences CEO David Happel sold $497,068 worth of shares at $7.76, representing 0.115% of the company's market cap. The sale is coded as open-market, though the filing states it was to cover tax withholding from RSU vesting.
Key Events · Ownership and Investor Activity · SGMT
-
CEO Sold $497K of Stock
President and CEO David Happel sold 64,051 shares at $7.76 on July 20, 2026, for total proceeds of $497,068. The sale represents 0.115% of the company's market cap.
-
Tax Withholding vs. Open-Market Sale
The filing states the shares were sold to cover tax withholding obligations from RSU vesting, but the transaction is coded as an open-market sale (Code S) rather than a routine tax withholding (Code F), making it a notable insider disposition.
-
Post-Transaction Ownership
Following the sale, Happel directly holds 741,570 shares, indicating the sale was a small fraction of his total position.
-
Recent Financing Context
The sale follows a $175 million public offering in April 2026 that significantly diluted existing shareholders and extended the company's cash runway.
Analysis · SGMT · Life Sciences
President and CEO David Happel sold 64,051 shares of Series A common stock at $7.76, generating $497,068. The sale represents 0.115% of the company's market cap. While the filing notes these shares were sold to cover tax withholding obligations from RSU vesting, the transaction is coded as an open-market sale (Code S) and not a routine tax withholding (Code F). This makes it a notable insider sale by the top executive, though the amount is modest relative to his remaining 741,570 shares. The sale comes after a recent $175 million public offering in April that significantly diluted existing shareholders, and amid a strategic shift toward dermatology. The insider activity signal over the past 90 days shows net distribution of $81,832, with this sale being the only open-market transaction.
How filings like this one have moved
In the 30 days to Sep 17, 2026, 29.7% of the 1739 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.34%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SGMT was trading at $7.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $431.3M. The 52-week trading range was $4.50 to $11.41. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.